NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21

by Ed Johnson
October 6, 2021
A A
EkoSonic(tm) Endovascular System

EkoSonic(tm) Endovascular System

Analysis found no intracerebral hemorrhages, low major bleeding rates; registry represents largest data set in interventional treatment of pulmonary embolism

LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 — Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. Data from the KNOCOUT PE registry – established to measure institutional adoption of a lower dose and lower-duration thrombolysis protocol for the EKOS system – confirmed the safety and efficacy of the EKOS system for the treatment of patients with intermediate-high and high-risk pulmonary embolism (PE).

“PE remains a life-threatening and complex disease, but these results provide an opportunity to advance patient care by showcasing evidence that proves a lower drug dose and shorter infusion duration of a thrombolytic agent may result in enhanced safety and efficacy,” said Keith M. Sterling, M.D., FSIR, Inova Alexandria Hospital, Alexandria, VA, study principal investigator.i “The findings in this registry analysis are very reassuring to physicians making critical evidence-based decisions for their patients in what are oftentimes emergent treatment situations.” 

The international registry of 489 patients across 83 centers included data from patients treated with the EKOS system who were provided a lower drug dose and shorter infusion duration of a thrombolytic agent than administered in previous studies, reflecting contemporary clinical practice. In the data, there were no intracerebral hemorrhagic (ICH) events, or brain bleeding events, with a low major bleedingii rate of 2.5%, compared to the rate previously observed with systemic thrombolysis treatment.iii Results also demonstrated a 23% post-procedure reduction in the main indicator of heart strain from PE, measured as right ventricular to left ventricular diameter ratio (RV/LV).

“As the largest prospective body of evidence in the interventional PE space to date, the KNOCOUT PE registry provides an accurate modern representation of patients with PE treated with the EKOS system every day,” said Michael R. Jaff, D.O., chief medical officer and vice president clinical affairs, technology and innovation, Peripheral Interventions, Boston Scientific. “The strong safety and efficacy findings exhibited in this registry add to the existing clinical evidence supporting the EKOS system as a treatment option that physicians can trust, as it is already the most studied interventional device in the PE space.”

The ultrasound technology used by the EKOS system accelerates thrombolysis – the breakdown of the clot – minimizing the time it takes to treat a patient and lowering the necessary thrombolytic dose, which can result in optimized outcomes and a lower risk of bleeding.

Tags: < Market
ShareTweetShareSend

Related Industries

Healthcare

Bayer Announces Changes to U.S. Country Leadership Team

June 9, 2023
Healthcare

Cardinal Health announces the merger of its Outcomes™ business into Transaction Data Systems and related partnership

June 6, 2023
Healthcare

Medtronic names Ken Washington new Chief Technology and Innovation Officer

June 2, 2023
Healthcare

BD Names Laura Boros President of Pharmaceutical Systems

June 2, 2023
Healthcare

Medtronic to acquire wearable insulin patch maker EOFlow

May 26, 2023
Healthcare

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

May 18, 2023

Jeanine Wai is appointed Vice President, Investor Relations North America of TotalEnergies

June 2, 2023

...

GE Hitachi Announces Intent to Transfer Ownership of Vallecitos Nuclear Center

May 10, 2023

...

Apple’s Worldwide Developers Conference to kick off June 5, 2023, with keynote address

May 24, 2023

...

Intel and SAP Embark on Strategic Collaboration to Expand Cloud Capabilities

May 18, 2023

...

BD Names Laura Boros President of Pharmaceutical Systems

June 2, 2023

...

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

May 18, 2023

...

Andrew Cornelia appointed to lead the new Mercedes-Benz charging network in North America – Christopher Trainor responsible for finance

June 1, 2023

...

Honeywell Completes First Flight Managed By Honeywell Anthem Integrated Flight Deck

May 13, 2023

...

IBM’s The Weather Company Continues to Be the World’s Most Accurate Forecaster Overall, Despite Growing Competition and Amid Weather’s Increased Impact

May 16, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NA-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NA-BIZ.COM All rights reserved.